Table 1 Demographic data of recruited breast cancer patients (n=223)
Parameters | Values |
|---|---|
Baseline | Â |
Age (years) | 48.4±10.2 (29–75) |
BMIa (kg m-2) | 23.36±3.79 (15.06-38.05) |
Tumor type | Â |
Infiltrating ductal carcinoma | 193 (86.55%) |
Ductal carcinoma in situ | 17 (7.62%) |
Others | 11 (4.93%) |
Unknown | 2 (0.90%) |
Side | Â |
Right | 100 (44.84%) |
Left | 114 (51.12%) |
Both | 9 (4.04%) |
Tumor size | Â |
<5cm | 159 (71.30%) |
≥5cm | 26 (11.66%) |
Unknown | 38 (17.04%) |
Lymph node involvement | Â |
Positive | 121 (53.81%) |
Negative | 90 (40.36%) |
Unknown | 12 (5.83%) |
TMN staging | Â |
Stages 0-2 | 154 (69.06%) |
Stages 3-4 | 30 (13.45%) |
Unknown | 39 (17.49%) |
ER/PR status | Â |
Single or double positive | 144 (64.57%) |
Negative | 52 (23.32%) |
Unknown | 27 (12.11%) |
Family history | Â |
Positive | 13 (5.83%) |
Negative | 203 (91.03%) |
Unknown | 7 (3.14%) |
Post-surgery follow-up | Â |
Therapies | Â |
TAM only | 92 (41.26%) |
TAM and chemotherapy | 56 (25.11%) |
TAM and radiotherapy | 10 (4.48%) |
Triple therapy | 55 (24.66%) |
Unknown | 10 (4.48%) |
Recurrence | Â |
With | 56 (25.11%) |
Without | 167 (74.89%) |
Mortality | Â |
With | 33 (14.80%) |
Without | 190 (85.20%) |
Progression-free | 165 (73.99%) |
Mean survival years | Â |
Recurrence-free | 9.26±5.31 (0.04-24.52) |
Overall | 10.14±5.11 (0.14-24.52) |